{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:28:25Z","timestamp":1789644505777,"version":"4.0.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mounting evidence suggests the addition of a \u03b2-lactam (BL) to daptomycin (DAP) results in synergistic in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) and bolsters the innate immune response to infection. This study\u2019s objective was to provide clinical translation to these experimental data and determine if DAP+BL combination therapy results in improved clinical outcomes compared with treatment with DAP alone in patients with MRSA bloodstream infections (BSIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, comparative cohort study conducted at 2 academic medical centers between 2008 and 2018. Adults with MRSA BSI treated with DAP for \u226572 hours and initiated \u22645 days of culture collection were included. Patients who received a BL for \u226524 hours and initiated \u226424 hours of DAP comprised the DAP+BL group. The primary outcome was composite clinical failure (60-day all-cause mortality and\/or 60-day recurrence). Analyses were adjusted for confounding using inverse probability of treatment weighting (IPTW).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 229 patients were included (72 DAP+BL and 157 DAP). In unadjusted and IPTW-adjusted analyses, DAP+BL was associated with significantly reduced odds of clinical failure (odds ratio [OR], 0.362; 95% confidence interval [CI], .164\u2013.801; adjusted OR, 0.386; 95% CI, .175\u2013.853). Adjusted analyses restricted to prespecified subgroups based on infection complexity and baseline health status were consistent with the main analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The addition of a BL to DAP was associated with improved clinical outcomes in patients with MRSA BSI. This study provides support to ongoing and future studies evaluating the impact of combination therapy for invasive MRSA infections.<\/jats:p>\n                    <jats:p>Patients treated with daptomycin plus a \u03b2-lactam for MRSA bloodstream infection had lower odds of composite clinical failure defined as 60-day all-cause mortality and\/or 60-day recurrence compared with patients treated with daptomycin monotherapy after adjusting for confounding variables using inverse probability of treatment weighting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciz746","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T15:10:27Z","timestamp":1564758627000},"page":"1-10","source":"Crossref","is-referenced-by-count":83,"title":["Daptomycin Plus \u03b2-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study"],"prefix":"10.1093","volume":"71","author":[{"given":"Sarah C J","family":"Jorgensen","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J","family":"Zasowski","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Clinical Pharmacy, Touro University California College of Pharmacy, Vallejo, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang D","family":"Trinh","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Clinical Pharmacy, University of California San Francisco School of Pharmacy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhamid M","family":"Lagnf","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Bhatia","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Sabagha","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda C","family":"Abdul-Mutakabbir","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alosaimy","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P","family":"Mynatt","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Detroit Medical Center, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Davis","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Pharmacy, Henry Ford Hospital, Detroit; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Rybak","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Pharmacy, Detroit Medical Center, Detroit, Michigan, USA"},{"name":"School of Medicine, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"2020062404334591400_CIT0001","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1473-3099(10)70285-1","article-title":"Clinical management of Staphylococcus aureus bacteraemia","volume":"11","author":"Thwaites","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2020062404334591400_CIT0002","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/CCM.0000000000001465","article-title":"A dysregulated balance of proinflammatory and anti-inflammatory host cytokine response early during therapy predicts persistence and mortality in Staphylococcus aureus bacteremia","volume":"44","author":"Minejima","year":"2016","journal-title":"Crit Care Med"},{"key":"2020062404334591400_CIT0003","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1086\/313650","article-title":"Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia","volume":"30","author":"Soriano","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020062404334591400_CIT0004","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/cid\/ciu583","article-title":"Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy","volume":"59","author":"Kullar","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020062404334591400_CIT0005","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020062404334591400_CIT0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study","volume":"54","author":"Moore","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020062404334591400_CIT0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC &gt;1 mg\/L: a multicenter evaluation","volume":"38","author":"Moise","year":"2016","journal-title":"Clin Ther"},{"key":"2020062404334591400_CIT0008","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1473-3099(09)70200-2","article-title":"Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions","volume":"9","author":"Moise","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2020062404334591400_CIT0009","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10096-007-0455-5","article-title":"High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia","volume":"27","author":"Sharma","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020062404334591400_CIT0010","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/AAC.00223-11","article-title":"In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates","volume":"55","author":"Mishra","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0011","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/infdis\/jis482","article-title":"Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients","volume":"206","author":"Mishra","year":"2012","journal-title":"J Infect Dis"},{"key":"2020062404334591400_CIT0012","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/AAC.01525-12","article-title":"\u03b2-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives","volume":"56","author":"Mehta","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0013","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tim.2018.06.005","article-title":"Can \u03b2-lactam antibiotics be resurrected to combat MRSA?","volume":"27","author":"Foster","year":"2019","journal-title":"Trends Microbiol"},{"key":"2020062404334591400_CIT0014","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020062404334591400_CIT0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drup.2013.10.002","article-title":"Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the \u201cseesaw effect\u201d: taking advantage of the back door left open?","volume":"16","author":"Ortwine","year":"2013","journal-title":"Drug Resist Updat"},{"key":"2020062404334591400_CIT0016","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.02071-15","article-title":"Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for \u03b2-lactam-daptomycin synergy","volume":"60","author":"Berti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0017","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2020062404334591400_CIT0018","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2020062404334591400_CIT0019","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.02192-12","article-title":"Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant \u03b2-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment","volume":"57","author":"Moise","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/23744235.2018.1448110","article-title":"Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"50","author":"Cortes-Penfield","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"2020062404334591400_CIT0021","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020062404334591400_CIT0022","first-page":"490","article-title":"Ceftaroline plus daptomycin for refractory methicillin- resistant Staphylococcus aureus bacteremia in a child","volume":"23","author":"Hall","year":"2018","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2020062404334591400_CIT0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methacillin-resistant Staphylococcus aureus bact","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0024","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"2020062404334591400_CIT0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2020062404334591400_CIT0026","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(94)90143-0","article-title":"New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service","volume":"96","author":"Durack","year":"1994","journal-title":"Am J Med"},{"key":"2020062404334591400_CIT0027","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0028","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020062404334591400_CIT0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2020062404334591400_CIT0031","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2020062404334591400_CIT0032","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2006.01.021","article-title":"Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia","volume":"55","author":"Kreisel","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020062404334591400_CIT0033","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"},{"key":"2020062404334591400_CIT0034","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1086\/375057","article-title":"Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia","volume":"36","author":"Lodise","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020062404334591400_CIT0035","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2020062404334591400_CIT0036","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/519283","article-title":"A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients","volume":"45","author":"McGregor","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020062404334591400_CIT0037","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"2020062404334591400_CIT0038","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"2020062404334591400_CIT0039","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2020062404334591400_CIT0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00109-013-1100-7","article-title":"Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus","volume":"92","author":"Sakoulas","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"2020062404334591400_CIT0041","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijantimicag.2008.05.007","article-title":"Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections","volume":"32","author":"Hsu","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2020062404334591400_CIT0042","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1128\/JCM.00448-13","article-title":"Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods","volume":"51","author":"Rybak","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2020062404334591400_CIT0043","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.02333-15","article-title":"The Staphylococcus aureus chaperone PrsA is a new auxiliary factor of oxacillin resistance affecting penicillin-binding protein 2A","volume":"60","author":"Jousselin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0044","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01634-16","article-title":"Molecular bases determining daptomycin resistance-mediated resensitization to beta-lactams (seesaw effect) in methicillin-resistant Staphylococcus aureus","volume":"61","author":"Renzoni","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020062404334591400_CIT0045","article-title":"Combination antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia: the CAMERA2 randomized controlled trial","author":"Davis","year":"2019","journal-title":"29th European Congress of Clinical Microbiology and Infectious Diseases, 13-16 April"},{"key":"2020062404334591400_CIT0046","article-title":"Two new trials of combination therapy for MRSA bacteremia answer some questions - and raise several new ones. HIV and ID Observations","author":"Sax","year":"2019","journal-title":"NEJM J Watch"},{"key":"2020062404334591400_CIT0047","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2020062404334591400_CIT0048","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"St\u00fcrmer","year":"2014","journal-title":"J Intern Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz746\/30162015\/ciz746.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/1\/1\/33422779\/ciz746.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/1\/1\/33422779\/ciz746.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T23:08:13Z","timestamp":1664060893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/1\/1\/5548921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,8,12]]},"published-print":{"date-parts":[[2020,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz746","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736413334.793571244","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.736413334.793587624","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2019,8,12]]}}}